Representative images of livers, including HCC tumors, from the different treatment groups are shown in Fig. 5A. The tumor numbers and the maximum tumor volume following CCR2 and CXCR2 antagonists-based TACE 6 weeks in HCC rats were reduced compared to the control group (Fig. 5B, C). The gene discussed is CCR2; the disease is hepatocellular carcinoma.